Due to health issues, this site is no longer maintained and will be shut down shortly.

NO:AZT ArcticZymes Technologies ASA

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics (IVD), and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsų, Norway.

36.16 NOK
As of 03/08/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Norway
Country of incorporation:  Norway
IPO date:  11/04/2005
Stock exchange:    Oslo Bors Asa
Exchange country:   Norway
Market cap:   3,679,630,848 NOK
Current dividend yield:   0.00%
Sedol:      B0MY6M3

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy